Supplementary file 1_Real-world anatomical and functional outcomes following Faricimab therapy in neovascular age-related macular degeneration: a one-year observational study.docx

One adverse event (vitreitis with ocular hypertension) occurred. Mixed-effects modelling showed significant longitudinal improvements in BCVA from baseline to months 6 and 12, with no significant time-by-treatment-history interaction. Baseline retinal fluid distribution was not significantly associated with differences in BCVA changes, while baseline SHRM status showed a significant time-by-SHRM interaction for BCVA, although multiplicity-adjusted between-group comparisons were not significant at any time point.

CRT decreased significantly from baseline to months 6 and 12, whereas the change between months 6 and 12 was not statistically significant. SHRM thickness also decreased significantly from baseline to months 6 and 12. Exploratory analyses by MNV subtype did not identify significant differences in 12-month BCVA or CRT.

In exploratory multivariable analysis, baseline BCVA was the only factor significantly associated with 12-month BCVA, whereas age, previous anti-VEGF treatment, and baseline SHRM were not.</p>Discussion<p>This retrospective two-center study showed significant improvements in BCVA and CRT after 12 months of Faricimab, with no statistically detectable difference in longitudinal BCVA according to previous anti-VEGF exposure.

Although baseline SHRM was associated with a significant time-by-SHRM interaction for BCVA, the absence of significant multiplicity-adjusted between-group differences limits interpretation of a differential response according to SHRM status. Given the small sample size and retrospective design, these findings should be interpreted cautiously.</p>